{
    "relation": [
        [
            "",
            "MK0518 100 mg b.i.d.",
            "MK0518 200 mg b.i.d",
            "MK0518 400 mg b.i.d.",
            "MK0518 600 mg b.i.d.",
            "EFV Combo Therapy"
        ],
        [
            "Description",
            "Cohort II Combined-Combination Therapy Phase MK0518 100 mg + tenofovir + lamivudine",
            "Cohort II Combined-Combination Therapy Phase MK0518 200 mg + tenofovir + lamivudine",
            "Cohort II Combined-Combination Therapy Phase MK0518 400 mg + tenofovir + lamivudine",
            "Cohort II Combined-Combination Therapy Phase MK0518 600 mg + tenofovir + lamivudine",
            "EFV Combo Therapy Phase - Cohort II efavirenz + tenofovir + lamivudine"
        ]
    ],
    "pageTitle": "A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED) - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00100048?sect=Xh015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987174.71/warc/CC-MAIN-20150728002307-00061-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 847001303,
    "recordOffset": 846985363,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{2520=For Part I (10 day monotherapy): 24-Jan-2005 to 04-May-2005, 2630=Part II (Dose Ranging): 14-Jun-2005 to 04-Oct-2006 (48 weeks); 14-Jun-2005 to 12-Jul-2010 (240 weeks)}",
    "textBeforeTable": "Reporting Groups Patients with Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA) of at least 5000 copies/mL and cluster of differentiation 4 (CD4) cell counts of at least 100 cells/mm3. All patients must have met laboratory criteria. 206 enrolled; 5 from Cohort I did not continue to the combination phase. Therefore 201 entered the combination phase. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Primary therapy period: For Part I (10 day monotherapy): 24-Jan-2005 to 04-May-2005 Part II (Dose Ranging): 14-Jun-2005 to 04-Oct-2006 (48 weeks); 14-Jun-2005 to 12-Jul-2010 (240 weeks) Multicenter (29) in the United States (14) and Ex-US (15) Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow",
    "textAfterTable": "Efavirenz 600 mg q.h.s. Cohort II Combined-Combination Therapy Phase efavirenz 600 mg every night at bedtime (q.h.s.) Participant Flow for 2 periods Period 1: \u00a0 Cohort I-Monotherapy Phase 10 Days \u00a0 \u00a0 MK0518 100 mg b.i.d. \u00a0 \u00a0 MK0518 200 mg b.i.d \u00a0 \u00a0 MK0518 400 mg b.i.d. \u00a0 \u00a0 MK0518 600 mg b.i.d. \u00a0 \u00a0 Placebo \u00a0 \u00a0 Efavirenz 600 mg q.h.s. \u00a0 STARTED \u00a0 \u00a0 7 \u00a0 \u00a0 7 \u00a0 \u00a0 6 \u00a0 \u00a0 8 \u00a0 \u00a0 7 \u00a0 \u00a0 0 [1] Treated \u00a0 \u00a0 7 \u00a0 \u00a0 7 \u00a0 \u00a0 6 \u00a0 \u00a0 8 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}